8-K: Ashland Inc. Reports Mixed Q1 Results, Provides Cautious Outlook for Fiscal 2024

Ashland Inc. announced its first quarter fiscal 2024 results, showing a sales decrease of 10% year-over-year, but also highlighted improved cash flow and a positive outlook for the remainder of the year.

Summary

• Ashland's first quarter fiscal 2024 sales were $473 million, a 10% decrease compared to the same quarter last year.
• Net income for the quarter was $26 million, or $0.51 per diluted share, down from $40 million in the prior year.
• Income from continuing operations was $28 million, or $0.54 per diluted share, compared to $42 million in the prior year.
• Adjusted income from continuing operations, excluding intangibles amortization, was $23 million, or $0.45 per diluted share, down from $54 million in the prior year.
• Adjusted EBITDA was $70 million, a 35% decrease from $108 million in the prior year.
• Cash flows from operating activities were $201 million, a significant increase from negative $29 million in the prior year.
• Ongoing free cash flow was $66 million, compared to negative $21 million in the prior year.
• The company repurchased 1.2 million shares during the quarter and has $900 million remaining under its share repurchase authorization.
• Ashland expects second quarter sales to be between $565 million and $585 million, with adjusted EBITDA between $115 million and $125 million.
• For the full fiscal year, Ashland anticipates sales between $2.15 billion and $2.25 billion and adjusted EBITDA between $460 million and $500 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like improved cash flow and share repurchases, the significant declines in sales and profitability, along with the cautious outlook, temper the overall sentiment. The company is facing challenges but is taking steps to address them.

Positives

• Cash flows from operating activities showed a significant improvement, reaching $201 million.
• Ongoing free cash flow improved to $66 million, indicating better cash generation.
• The company repurchased 1.2 million shares, showing confidence in its stock value.
• There is a potential recovery in demand with improving trends in January and February.
• Ashland is making progress on portfolio optimization activities to improve margins and reduce earnings volatility.
• The company is focused on disciplined production levels and inventory management.
• Foreign currency had a favorable impact on sales by approximately one percent.

Negatives

• Sales decreased by 10% year-over-year to $473 million.
• Net income decreased to $26 million from $40 million in the prior-year quarter.
• Adjusted EBITDA decreased by 35% to $70 million.
• The Life Sciences segment saw a 3% sales decrease due to normalized supply of Polyvinylpyrrolidone (PVP) and lower demand in nutrition.
• The Personal Care segment experienced a 7% sales decrease due to lower volumes in skin-care and oral-care.
• The Specialty Additives segment saw a 15% sales decrease due to lower volumes and pricing in architectural coatings.
• The Intermediates segment experienced a 39% sales decrease due to lower pricing and volumes.

Risks

• The company is facing challenges in several segments, including Life Sciences, Personal Care, Specialty Additives, and Intermediates.
• Lower production volumes and unfavorable absorption impacts are negatively affecting profitability.
• The company is exposed to market demand dynamics and potential fluctuations in end-market demand.
• There is a risk that the expected recovery in demand may not materialize as anticipated.
• The company is exposed to foreign currency fluctuations, although this had a positive impact in the first quarter.
• The company is exposed to risks associated with the ongoing Ukraine/Russia and Israel/Hamas conflicts.

Future Outlook

Ashland expects second quarter sales to be between $565 million and $585 million, with adjusted EBITDA between $115 million and $125 million. For the full fiscal year, Ashland anticipates sales between $2.15 billion and $2.25 billion and adjusted EBITDA between $460 million and $500 million. The company anticipates a partial return to more typical margins during the second quarter.

Management Comments

• Guillermo Novo, chair and chief executive officer, stated that financial results in the December quarter yielded adjusted EBITDA above the outlook range issued on November 8, 2023.
• Novo noted that customer demand was generally consistent with expectations in the first quarter.
• Novo mentioned that the company is cautiously optimistic about improving demand trends experienced in January with follow-through order build into February.
• Novo emphasized that Ashland will remain disciplined in its production levels, targeting to produce to near-term demand.
• Novo highlighted the company's focus on strategic priorities to execute, globalize, innovate, and acquire.
• Novo stated that Ashland believes its stock is an attractive use of capital, as demonstrated by the repurchase of an additional $100 million of Ashland shares during the quarter.

Industry Context

Ashland operates in the global additives and specialty ingredients market, serving various consumer and industrial sectors. The company's performance is influenced by market demand dynamics, raw material costs, and supply chain conditions. The results reflect a mixed performance with some segments facing headwinds while others show signs of recovery. The company's focus on portfolio optimization and strategic priorities aligns with industry trends towards efficiency and growth.

Comparison to Industry Standards

• Ashland's 10% sales decrease is worse than some of its peers in the specialty chemicals industry, which have shown more resilience in the current economic climate. For example, companies like Dow and DuPont have reported smaller sales declines or even growth in some segments.
• The 35% decrease in adjusted EBITDA is significant and indicates that Ashland is facing more challenges in profitability compared to industry benchmarks. Companies like BASF and Evonik have reported better EBITDA performance, although they also face similar headwinds.
• Ashland's cash flow improvement is a positive sign, but it needs to be sustained to match the performance of industry leaders. Companies like Sherwin-Williams and PPG have demonstrated more consistent cash flow generation.
• The share repurchase program is a common practice in the industry, but the impact on shareholder value will depend on the company's overall performance and market conditions. Companies like Ecolab and Air Products have also engaged in share repurchases, but their stock performance has varied.
• The consolidation of CMC production capacity is a strategic move to improve efficiency, which is a common practice in the industry. Companies like Celanese and Eastman have also undertaken similar restructuring efforts to optimize their operations.

Stakeholder Impact

• Shareholders may be concerned about the decrease in sales and profitability, but may be encouraged by the improved cash flow and share repurchase program.
• Employees may be affected by the consolidation of production capacity and closure of the Hopewell, Virginia facility.
• Customers may experience changes in supply and pricing due to the company's strategic adjustments.
• Suppliers may be impacted by changes in production levels and demand.
• Creditors may be reassured by the improved cash flow, but may be concerned about the decrease in profitability.

Next Steps

• Ashland will continue to monitor demand trends and adjust production levels accordingly.
• The company will proceed with the consolidation of its CMC production capacity in Alizay, France, and close its Hopewell, Virginia facility in the second quarter of 2024.
• Ashland will continue to assess actions to improve its industrial methylcellulose (MC) and hydroxyethycellulose (HEC) businesses.
• The company will host an earnings call and webcast on January 31, 2024, to discuss the first quarter results and outlook.

Key Dates

Keywords

Ashland, financial results, EBITDA, sales, cash flow, share repurchase, specialty ingredients, additives, Life Sciences, Personal Care, Specialty Additives, Intermediates